You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Chlorphentermine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for chlorphentermine hydrochloride and what is the scope of patent protection?

Chlorphentermine hydrochloride is the generic ingredient in one branded drug marketed by Parke Davis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for chlorphentermine hydrochloride
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 40
Patent Applications: 87
DailyMed Link:chlorphentermine hydrochloride at DailyMed
Medical Subject Heading (MeSH) Categories for chlorphentermine hydrochloride

US Patents and Regulatory Information for chlorphentermine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis PRE-SATE chlorphentermine hydrochloride TABLET;ORAL 014696-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Chlorphentermine hydrochloride Market Analysis and Financial Projection Experimental

Chlorpheniramine Maleate vs. Chlorphentermine Hydrochloride: A Market Dynamics Analysis

While the query specifically asks about Chlorphentermine Hydrochloride, it is crucial to note that the available data primarily focuses on Chlorpheniramine Maleate. However, we can draw some distinctions and provide insights based on the information available.

Chlorphentermine Hydrochloride: An Overview

Chlorphentermine hydrochloride is a sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of dextroamphetamine and has been implicated in lipid storage disorders and pulmonary hypertension[2].

Market Dynamics

Unlike Chlorpheniramine Maleate, which has a well-defined market trajectory, Chlorphentermine Hydrochloride does not have a significant market presence due to several reasons:

Historical Use and Side Effects

Chlorphentermine hydrochloride was used as an anorectic but has largely been discontinued due to its serious side effects, including lipid storage disorders and pulmonary hypertension. This has led to a negligible market for this drug.

Regulatory Status

Given its adverse effects, Chlorphentermine hydrochloride is not widely approved or recommended by regulatory bodies, further limiting its market potential.

Alternative Treatments

The availability of safer and more effective alternatives for weight loss and other conditions has significantly reduced the demand for Chlorphentermine hydrochloride.

Financial Trajectory

No Significant Market Value

Due to its discontinued use and lack of regulatory approval, Chlorphentermine hydrochloride does not have a notable market value. The financial trajectory of this drug is essentially flat, with no projected growth.

Comparison with Chlorpheniramine Maleate

In contrast, Chlorpheniramine Maleate, an antihistamine used to treat allergic conditions, has a robust market. Here are some key financial and market dynamics for Chlorpheniramine Maleate:

Market Size and Growth

The Chlorpheniramine Maleate market was valued at $468.6 million in 2022 and is projected to reach $751.4 million by 2032, growing at a CAGR of 4.9% from 2023 to 2032[1].

Regional Dominance

North America accounts for the majority share of the Chlorpheniramine Maleate market and is expected to remain dominant during the forecast period. The Asia-Pacific region is expected to witness the highest growth rate due to increasing prevalence of allergic conditions and rising consumer awareness[1][3].

Key Drivers and Restraints

The growth of the Chlorpheniramine Maleate market is driven by the increasing prevalence of allergic conditions, advancements in healthcare infrastructure, and rising R&D activities. However, the availability of alternative medications and potential side effects of Chlorpheniramine Maleate are expected to hamper the market growth[1][3].

Key Takeaways

  • Chlorphentermine Hydrochloride: This drug has no significant market presence due to its discontinued use and serious side effects.
  • Chlorpheniramine Maleate: This antihistamine has a growing market, driven by increasing allergic conditions and advancements in healthcare, with a projected market size of $751.4 million by 2032.

FAQs

What is Chlorphentermine Hydrochloride used for?

Chlorphentermine hydrochloride was formerly used as an anorectic but has been discontinued due to serious side effects.

Why is Chlorphentermine Hydrochloride not widely used?

It is not widely used due to its association with lipid storage disorders and pulmonary hypertension.

What is the market size of Chlorpheniramine Maleate?

The Chlorpheniramine Maleate market was valued at $468.6 million in 2022 and is projected to reach $751.4 million by 2032.

Which region dominates the Chlorpheniramine Maleate market?

North America dominates the Chlorpheniramine Maleate market and is expected to remain so during the forecast period.

What are the key drivers of the Chlorpheniramine Maleate market?

The key drivers include the increasing prevalence of allergic conditions, advancements in healthcare infrastructure, and rising R&D activities.

Cited Sources

  1. Allied Market Research: Chlorpheniramine Maleate Market Statistics and Forecast - 2032
  2. DrugBank Online: Chlorphentermine hydrochloride
  3. Fairfield Market Research: Global Chlorpheniramine Maleate Market Forecast
"Chlorphentermine hydrochloride is a sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of dextroamphetamine and has been implicated in lipid storage disorders and pulmonary hypertension." - DrugBank Online[2]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.